A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Condition:   Refractory B-cell Acute Lymphoblastic Leukemia Intervention:   Drug: Mosunetuzumab Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials